

DAFTAR PUSTAKA

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Vol. 109, Journal of Autoimmunity. Academic Press; 2020.
2. Worldometer. Corona Virus Update [Internet]. 2022 [cited 2022 Feb 2]. Available from: <https://www.worldometers.info/coronavirus/>
3. Wang Z, Qiang W, Ke H. A Handbook of 2019-nCoV Pneumonia Control and Prevention. Hubei Science and technology press. 2020;
4. Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, et al. Towards effective COVID-19 vaccines: Updates, perspectives and challenges (Review). Vol. 46, International journal of molecular medicine. NLM (Medline); 2020. p. 3–16.
5. Nugroho SA, Hidayat IN. Efektivitas Dan Keamanan Vaksin Covid-19 : Studi Referensi.
6. World Health Organization. Global manual on surveillance of adverse events following immunization [Internet]. 2004 [cited 2021 Dec 1]. 26 p. Available from: <https://apps.who.int/iris/handle/10665/206144>
7. Kemkes RI. Penularan, Perawatan dan Kematian akibat COVID-19 pada Tenaga Kesehatan di DKI Jakarta, Januari-Juni 2021 [Internet]. Jakarta; 2021 [cited 2022 Feb 2]. Available from: <https://sehatnegeriku.kemkes.go.id/wp-content/uploads/2021/08/Studi-Terbaru-Efektifitas-Vaksinasi.pdf>
8. World Health Organization. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2022 Feb 2]. Available from: <https://covid19.who.int/>
9. Kementerian Kesehatan RI. Vaksin Dashboard [Internet]. [cited 2022 Feb 2]. Available from: <https://vaksin.kemkes.go.id/#/vaccines>
10. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *The Lancet*. 2021 May 15;397(10287):1819–29.
11. Hafizzanovian H, Oktariana D, Apriansyah MA, Yuniza Y. Peluang Terjadinya Immunization Stress-Related Response (ISRR) Selama Program Vaksinasi COVID-19. *Jurnal Kedokteran dan Kesehatan : Publikasi Ilmiah Fakultas Kedokteran Universitas Sriwijaya*. 2021 Aug 30;8(3):211–22.

12. Ranuh IGNG, Hadinegoro SR, Kartasasmita CB, Ismoedijanto I, Soedjatmiko S, Gunardi H, et al. Pedoman Imunisasi di Indonesia. Vol. 6, Badan Penerbit Ikatan Dokter Anak Indonesia. 2017.
13. Shivani Singh SA, Silky Rai SW. Adverse Event following Immunization (AEFI) and COVID-19 Vaccination: A Review. *International Journal of Current Microbiology and Applied Sciences*. 2021 Jun 20;10(6):555–65.
14. Satuan Tugas Penanganan COVID-19. Informasi Tentang KIPI atau Reaksi Setelah Vaksinasi COVID-19 [Internet]. 2021 [cited 2022 Feb 6]. Available from: <https://kipi.covid19.go.id/>
15. Sultana A, Shahriar S, Tahsin MR, Mim SR, Fatema KR, Saha A, et al. A retrospective cross-sectional study assessing self-reported adverse events following immunization (AEFI) of the COVID-19 vaccine in Bangladesh. *Vaccines (Basel)*. 2021 Oct 1;9(10).
16. Supangat, Sakinah EN, Nugraha MY, Qodar TS, Mulyono BW, Tohari AI. COVID-19 Vaccines Programs: adverse events following immunization (AEFI) among medical Clerkship Student in Jember, Indonesia. *BMC Pharmacology and Toxicology*. 2021 Dec 1;22(1).
17. Menteri Kesehatan Republik Indonesia. Petunjuk Teknis Pelaksanaan Vaksinasi Dalam Rangka Penanggulangan Pandemi Corona Virus Disease 2019 (Covid-19). KEMENKES RI, HK.01.07/MENKES/4638/2021 Indonesia: jdih.kemkes.go.id; 2021.
18. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Vol. 87, *Indian Journal of Pediatrics*. Springer; 2020. p. 281–6.
19. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Vol. 5, *Nature Microbiology*. 2020.
20. WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it [Internet]. World Health Organization. [cited 2021 Dec 15]. Available from: [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)
21. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*. 2020;395(10223).
22. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine* [Internet]. 2020 Mar 5 [cited 2021 Dec 16];382(10):970–1. Available from: <https://www.nejm.org/doi/10.1056/NEJMc2001468>

23. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [Internet]. World Health Organization. [cited 2021 Dec 16]. Available from: https://www.who.int/health-topics/middle-east-respiratory-syndrome-coronavirus-mers#tab=tab_1
24. Huang B, Ling R, Cheng Y, Wen J, Dai Y, Huang W, et al. Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. Vol. 18, *Molecular Therapy - Methods and Clinical Development*. 2020.
25. Wasito, Hatari W. Corona Virus (Sars, Mers, Covid-19). Wasito, Hatari W, editors. Yogyakarta: Lily Publisher; 2020.
26. Zheng QL, Duan T, Jin LP. Single-cell RNA expression profiling of ACE2 and AXL in the human maternal-Fetal interface. Vol. 4, *Reproductive and Developmental Medicine*. 2020.
27. Wu P, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Vol. 25, *Eurosurveillance*. 2020.
28. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. Vol. 16, *Pediatrics i Medycyna Rodzinna*. 2020.
29. Azhar Y. Peluang dan Tantangan Produksi Vaksin Coronavirus Disease 2019 (COVID-19) Studi Literatur. [Padang]; 2021.
30. Satuan Tugas Penanganan COVID-19. Pengendalian COVID-19 dengan 3M, 3T, Vaksinasi, Disiplin, Kompak, dan Konsisten. 2021;
31. Nagarajan C. In Search of a COVID-19 Vaccine. *IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)*. 2020;19(5):22–9.
32. Ndwandwe D, Wiysonge CS. COVID-19 vaccines. *Current Opinion in Immunology* [Internet]. 2021 Aug 1 [cited 2021 Dec 21];71:111–6. Available from: <https://doi.org/10.1016/j.coi.2021.07.003>
33. Makmum A, Hazhiyah SF. Tinjauan Terkait Pengembangan Vaksin COVID-19. *Molucca Medica*. 2020;13(2):52–9.
34. Hasson SSAA, Al-Busaidi JKZ, Sallam TA. The past, current and future trends in DNA vaccine immunisations. Vol. 5, *Asian Pacific Journal of Tropical Biomedicine*. 2015.
35. Permata Sari M, Zatil Izzah A, Perdana Harmen A. Gambaran Kejadian Ikutan Pasca Imunisasi pada Anak yang Mendapatkan Imunisasi Difteri Pertusis dan Tetanus di Puskesmas Seberang Padang Kota Padang [Internet]. Vol. 7, *Jurnal Kesehatan Andalas*. 2018. Available from: <http://jurnal.fk.unand.ac.id>

36. Lovia S, Sari YO, Almasdy D, Amelin F. Studi Kualitatif Pengetahuan Perawat terhadap Reaksi Obat yang Tidak Dikehendaki (ROTD) di Bangsal Rawat Inap Anak RSUP Dr. M. Djamil Padang. *Jurnal Sains Farmasi & Klinis*. 2019 Aug 29;6(2):95.
37. Hadinegoro SR. Kejadian Ikutan Pasca Imunisasi. *Sari Pediatri*. 2000;2(1):2–10.
38. World Health Organization. Modul 3: Kejadian Ikutan Pasca Imunisasi [Internet]. [cited 2022 Feb 18]. Available from: <https://in.vaccine-safety-training.org/classification-of-aefis.html>
39. BPOM RI. Penerbitan EUA Vaksin CoronaVac Sinovac oleh Badan POM [Internet]. BPOM RI. 2021 [cited 2022 Feb 22]. Available from: <https://www.pom.go.id/new/view/more/berita/20883/Badan-POM-Terbitkan-EUA--Vaksin-CoronaVac-Sinovac-Siap-Disuntikkan.html>
40. BPOM RI. Penerbitan UAE Vaksin Sinopharm oleh Badan POM [Internet]. BPOM RI. 2021 [cited 2022 Feb 22]. Available from: <https://www.pom.go.id/new/view/more/berita/22112/Tambah-Amunisi-Vaksinasi--Badan-POM-Terbitkan-EUA-Vaksin-Sinopharm-.html>
41. Aryal S, Devbhandari RP, Shrestha A, Rajbhandari P, Shakya T, Tuladhar S, et al. Adverse events following Immunization with Sinopharm (Vero Cell) inactivated COVID-19 vaccine. *General Section Original Article Journal of Patan Academy of Health Sciences* [Internet]. 2021;8(2):18–24. Available from: <https://doi.org/10.3126/jpahs>.
42. BPOM RI. Penerbitan UAE vaksin AstraZeneca oleh Badan POM [Internet]. BPOM RI. 2021 [cited 2022 Feb 22]. Available from: <https://www.pom.go.id/new/view/more/berita/21441/Vaksin-AstraZeneca-Resmi-Mendapatkan-EUA-dari-Badan-POM.html>
43. BPOM RI. Penerbitan EUA Moderna COVID-19 Vaccine Sebagai Vaksin Pertama dari Platform mRNA oleh Badan POM [Internet]. BPOM RI. 2021 [cited 2022 Feb 22]. Available from: <https://www.pom.go.id/new/view/more/pers/615/Badan-POM-Terbitkan-EUA-Moderna-COVID-19-Vaccine-Sebagai-Vaksin-Pertama-dari-Platform-mRNA.html>
44. Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: A post-marketing Italian study conducted between 1 January and 28 February 2021. *European Journal of Hospital Pharmacy*. 2021;
45. Nisak L, Suparningtyas JF, Kuncoro H. Studi Evaluasi Efek Samping Penggunaan Vaksin COVID-19 Terhadap Masyarakat Sebatik Timur. *Proceeding of Mulawarman Pharmaceuticals Conferences* [Internet]. 2021 Dec 31;14:138–44. Available from: <https://prosiding.farmasi.unmul.ac.id/index.php/mpc/article/view/564>

46. Parida SP, Sahu DP, Singh AK, Alekhya G, Subba SH, Mishra A, et al. Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India. *Journal of Medical Virology*. 2022;94(6).
47. Badan Pusat Statistik. Badan Pusat Statistik Kota Padang [Internet]. BPS Kota Padang. 2020 [cited 2022 Jun 5]. Available from: <https://padangkota.bps.go.id/indicator/12/31/1/jumlah-penduduk-menurut-jenis-kelamin.html>
48. Permenkes. Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016. Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019. 2016;
49. Lidiana EH, Mustikasari H, Pradana KA, Permatasari A, Tirtonegoro S, Sayidiman Magetan RD, et al. Gambaran karakteristik kejadian ikutan pasca vaksinasi covid-19 pada tenaga kesehatan alumni universitas 'aisyiyah surakarta. *Jurnal Ilmiah Kesehatan*. 2021;11-6.
50. Possible Side effects from Vaccines | CDC [Internet]. [cited 2022 Jun 2]. Available from: <https://www.cdc.gov/vaccines/vac-gen/side-effects.htm>
51. Laporan Capaian Kinerja Presiden RI. Laporan Capaian Kinerja 2021. 2021 [cited 2022 Jun 16]; Available from: <https://capaiankinerja.presidentri.go.id/>
52. Rakhmadhani I, Yulida E, Fauzan A, Jaelani AK. Adverse Events Following Immunization Post Moderna (mRNA1273) Booster Vaccination after Two Primary Doses of CoronaVac. *International Journal of Health Sciences*. 2022 Apr 1;6(1):160-73.
53. Kim SH, Wi YM, Yun SY, Ryu JS, Shin JM, Lee EH, et al. Adverse Events In Healthcare Workers After The First Dose Of Chadox1 Ncov-19 Or Bnt162b2 Mrna Covid-19 Vaccination: A Single Center Experience. *Journal of Korean Medical Science*. 2021;36(14):1-8.
54. Kaur U, Ojha B, Pathak BK, Singh A, Giri KR, Singh A, et al. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. *eClinicalMedicine*. 2021 Aug 1;38.
55. Jaiswal KM, Dudhgaonkar S, Raghute L, Uike P, Kohli S, Anand I. An assessment of AEFI COVID-19 vaccination in health care workers at a Tertiary Health Care Center in central India. *Microbiology Research International* [Internet]. 2021 Jun;9(2):46-50. Available from: http://www.netjournals.org/z_MRI_21_017.html
56. Kitagawa H, Kaiki Y, Sugiyama A, Nagashima S, Kurisu A, Nomura T, et al. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan. *Journal of Infection and Chemotherapy*. 2022 Apr 1;28(4):576-81.

57. Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmerón G, et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. *eBioMedicine*. 2022 Jan 1;75.
58. Kemenkes RI. Tanya Jawab COVID-19: Apakah saya bisa memilih jenis vaksin booster yang diterima? | Covid19.go.id [Internet]. Covid19.go.id. 2022 [cited 2022 Jul 10]. Available from: <https://covid19.go.id/artikel/2022/01/11/apakah-saya-bisa-memilih-jenis-vaksin-booster-yang-diterima>
59. Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. 2021 Sep 1;15(5).
60. World Health Organization. Karakteristik produk COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac®. 2021;
61. World Health Organization. Karakteristik produk COMIRNATY® Vaksin mRNA COVID-19 (modifikasi nukleosida). 2021 [cited 2022 Jun 13]; Available from: <https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-mrna-vaccine-nucleoside-modified->
62. World Health Organization. Karakteristik produk Vaksin COVID-19 Moderna (mRNA-1273). 2021 Feb 7;
63. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. *The Lancet Infectious Diseases*. 2021 Jul 1;21(7):939–49.
64. Fischinger S, Boudreau CM, Butler AL, Streeck H, Alter G. Sex differences in vaccine-induced humoral immunity. Available from: <https://doi.org/10.1007/s00281-018-0726-5>
65. Klein SL, Marriott I, Fish EN, Feinstone WH. Sex-based differences in immune function and responses to vaccination. Available from: <https://academic.oup.com/trstmh/article/109/1/9/1921905>
66. Texas Biomed. Age, sex and waning COVID-19 antibodies. Texas Biomedical Research Institute [Internet]. 2021 [cited 2022 Jun 17]; Available from: <https://www.txbiomed.org/news-press/news/dropping-antibodies-covid/>
67. Pfizer-BioNTech COVID-19 Vaccine Reactions & Adverse Events | CDC [Internet]. [cited 2022 Jun 17]. Available from: <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html>

68. Departemen Gizi Kesehatan Masyarakat F, Kesehatan Masyarakat F. Respons Imunitas Yang Rendah Pada Tubuh Manusia Usia Lanjut. Vol. 10, JUNI. 2006.
69. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. *JAMA Network Open*. 2021 Dec 22;4(12).
70. Vasan A, Kenyon CC, Feudtner C, Fiks AG, Venkataramani AS. Association of WIC Participation and Electronic Benefits Transfer Implementation. *JAMA Pediatrics*. 2021 Jun 1;175(6):609–16.
71. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 Antibody Response following Vaccination with BNT162b2 and mRNA-1273. *JAMA - Journal of the American Medical Association*. 2021 Oct 19;326(15):1533–5.
72. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M, El-Gamal Y, et al. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. Vol. 14, *World Allergy Organization Journal*. Elsevier Inc.; 2021.

